Showing results (231-240 of 241) with videos related to
Sort By:
Pageof 25
The Oncologist|March 14, 2026
Telemedicine as a Gateway to Early-Phase Oncology Trials: Lessons from 14,000 Patients and Future Directions for Global Access and EquityCarlos Torrado, Clark R Andersen, Lei Kang, et al.Oncotarget|September 3, 2015
BRAF mutation testing with a rapid, fully integrated molecular diagnostics systemFilip Janku, Bart Claes, Helen J Huang, et al.The Lancet. Oncology|June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trialPanagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.JCO Precision Oncology|October 16, 2024
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyFrancis P Worden, Evan Pisick, Michael Rothe, et al.Nature Medicine|March 14, 2025
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trialYuxiang Ma, Yunpeng Yang, Yan Huang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced CancerFilip Janku, Shile Zhang, Jill Waters, et al.Cell Reports. Medicine|May 21, 2026
Biomarker study of pembrolizumab in patients with advanced rare cancersAung Naing, Xiqi Li, Qi Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.Journal for Immunotherapy of Cancer|March 20, 2020
Phase 2 study of pembrolizumab in patients with advanced rare cancersAung Naing, Funda Meric-Bernstam, Bettzy Stephen, et al.Pageof 25